FilingSEC EDGAR8-K
Tenax Therapeutics Reports Phase 3 LEVEL Results and Strategic Pivot for LEVEL-2
· SEC accepted
StagePhase 3
Filing content
Tenax Therapeutics reported that its Phase 3 LEVEL trial missed the primary endpoint but identified efficacy in specific patient subgroups, which will inform the protocol for the upcoming LEVEL-2 trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…